Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 850 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Benzodiazepine Clear all

Conditions: Medication Abuse
Interventions: PDMP Check CDS; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 89 Years
Enrollment: 89,871 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Surgery, Aging
Interventions: Peer Comparison Feedback, Patient Informational Letter; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 65 Years and older
Enrollment: 517,611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Type 2 Diabetes Mellitus (T2DM), Obesity
Interventions: Placebo, Rosuvastatin, Midazolam, Omeprazole, PF-06954522; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Anaheim, California • South Miami, Florida

Conditions: Driving Performance
Interventions: Rapastinel, Alprazolam, Ketamine, Rapastinel Matched Placebo, Alprazolam Matched Placebo, Ketamine Matched Placebo; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Clemente, California

Conditions: Meniscus Disorder, Narcotic Use
Interventions: Celecoxib, Hydrocodon/Acetaminophen, Ketorolac, Gabapentin, Acetaminophen, Diazepam; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Antipsychotics, Pregnancy
Interventions: Antipsychotics, Non-antipsychotic medication, No Medication; Drug · Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia
Interventions: Olanzapine, Risperidone; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 16 Years to 40 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2007
U.S. locations: 2
States / cities: Glen Oaks, New York • The Bronx, New York

Conditions: Healthy Volunteers
Interventions: KarXT, Midazolam, Fexofenadine, Digoxin; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Schizophrenia
Interventions: olanzapine, olanzapine pamoate depot; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 13
States / cities: Escondido, California • National City, California • Orange, California + 10 more

Conditions: Depression
Interventions: Clemastine Fumarate, Placebo; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 60 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Olanzapine (Zyprexa), Typicals; Drug
Lead sponsor: VA Connecticut Healthcare System; Federal
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV-infection/AIDS
Interventions: Cenicriviroc, Dolutegravir, Midazolam; Drug
Lead sponsor: Tobira Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
Interventions: VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine + Nab-paclitaxel, Pembrolizumab, Defactinib, Midazolam, Repaglinide; Drug
Lead sponsor: Verastem, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 616 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 10 more

Conditions: Drug Interaction, Healthy Volunteer
Interventions: Entinostat, Midazolam; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Amnesia, Pain, Anesthesia
Interventions: Dexmedetomidine, Midazolam, Peripheral nerve stimulation, Ketamine; Drug · Device
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 39 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Substance Use Disorders, Opiate Dependence, Opiate Withdrawal Syndrome, Opioid-use Disorder, Alcohol Withdrawal, Alcohol Abuse, Alcohol Use Disorder, Cocaine Abuse, Cocaine Use Disorder, Cocaine Withdrawal, Benzodiazepine Abuse, Benzodiazepine Dependence, Substance Abuse, Heroin Overdoses, Heroin Withdrawal, Heroin Abuse
Interventions: Six Step Model of Self-Forgiveness, Treatment as Usual (TAU); Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: McKeesport, Pennsylvania

Conditions: Post Traumatic Stress Disorder
Interventions: clonazepam and paroxetine; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: LY3509754, Placebo, Itraconazole, Midazolam; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Anaheim, California • Dallas, Texas

Conditions: Post-Traumatic Stress Disorder
Interventions: Cognitive Behavioral Therapy, Motivational Interviewing, FDA-Approved Anti-Anxiety Medications, Standard Care Control; Behavioral · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Colonoscopy, Colonic Polyps
Interventions: AQUAVAN® (fospropofol disodium) Injection, Midazolam HCl; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 20
States / cities: Huntsville, Alabama • Phoenix, Arizona • Atlanta, Georgia + 16 more

Conditions: Healthy
Interventions: alprazolam, Placebo, PF-00572778; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Sarcoma, Alveolar Soft Part
Interventions: Cediranib, Sunitinib, Prochlorperazine, Promethazine, Benzodiazepine, Filgrastim, Sargramostim, Lomotil, Loperamide, Vitamin B6, Aquaphor, Acetaminophen, Levothyroxine, Warfarin; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years to 120 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Panic Disorder
Interventions: Clonazepam, Sertraline, Cognitive behavioral therapy; Drug · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depression, Anxiety, Fear, Depression, Anxiety and Fear, Anxiety Disorders, Anxious Depression
Interventions: Lorazepam, Placebo; Drug · Other
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Search by objective public record fields.

A Prospective Evaluation of Colorado's New Statutory PDMP Mandates: Compliance and Patient Outcomes

De-adopting Routine Preoperative Benzodiazepines for Older Surgical Patients

A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus

Assessment of Effect of Rapastinel on Driving Performance

Nonopioid Analgesia After Arthroscopic Meniscus Surgery

Maternal And Infant Antipsychotic Study

Treatment for First-Episode Schizophrenia

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

Zyprexa and Task Engagement in Schizophrenia

Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects

Memory Modulation by Pain During Anesthesia

The Effect of Self-Forgiveness on Self-Stigma in Addiction.

Clonazepam and Paroxetine for Rapid Treatment of Post-Traumatic Stress Disorder

A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants

Patient-Centered Collaborative Care for Preventing Post-Traumatic Stress Disorder After Traumatic Injury

Study of AQUAVAN® Injection (AQUAVAN; Fospropofol Disodium) for Sedation During Colonoscopy

Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Therapies for Treatment-Resistant Panic Disorder Symptoms

Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression